Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study Academic Article Article uri icon

Overview

MeSH Major

  • Embryo Transfer
  • Fetal Death
  • Pregnancy, Twin
  • Premature Birth

abstract

  • Crizotinib is well tolerated with rapid, durable responses in patients with ALK-positive NSCLC. There seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed.

publication date

  • October 2012

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(12)70344-3

PubMed ID

  • 22954507

Additional Document Info

start page

  • 1011

end page

  • 9

volume

  • 13

number

  • 10